These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 12671888

  • 1. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 2. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F, López San Román A, Algaba A, van Domselaar M, Carneros JA, Rivero M, Piqueras B, Valer MP.
    Gastroenterol Hepatol; 2008 Dec 13; 31(10):629-32. PubMed ID: 19174078
    [Abstract] [Full Text] [Related]

  • 4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 13; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P.
    Gut; 2007 Sep 13; 56(9):1226-31. PubMed ID: 17229796
    [Abstract] [Full Text] [Related]

  • 6. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ.
    Gastroenterology; 2003 Apr 13; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract] [Full Text] [Related]

  • 7. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan 13; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

  • 8. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 13; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 9. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.
    Colorectal Dis; 2005 Mar 13; 7(2):164-8. PubMed ID: 15720356
    [Abstract] [Full Text] [Related]

  • 10. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 13; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 11. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone.
    Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K.
    J Clin Gastroenterol; 2007 Aug 13; 41(7):677-81. PubMed ID: 17667052
    [Abstract] [Full Text] [Related]

  • 12. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG.
    Eur J Gastroenterol Hepatol; 2009 Sep 13; 21(9):1042-8. PubMed ID: 20139856
    [Abstract] [Full Text] [Related]

  • 13. Infusion reactions and their management.
    Mayer L, Young Y.
    Gastroenterol Clin North Am; 2006 Dec 13; 35(4):857-66. PubMed ID: 17129817
    [Abstract] [Full Text] [Related]

  • 14. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 16. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
    N Engl J Med; 1999 May 06; 340(18):1398-405. PubMed ID: 10228190
    [Abstract] [Full Text] [Related]

  • 17. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):851-8. PubMed ID: 16918890
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA.
    Am J Gastroenterol; 2000 Dec 01; 95(12):3490-7. PubMed ID: 11151882
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 20. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.
    Aliment Pharmacol Ther; 2008 Jul 01; 28(2):221-7. PubMed ID: 18485127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.